Adam Gault J.P. Morgan has downgraded Dyne Therapeutics ( NASDAQ: DYN ) to neutral from overweight, citing the stock’s outperformance this year.
The investment bank noted that while Dyne ( DYN ) shares have underperformed since September, they’re still up around 150% year-to-date versus the broader biotech market..